Immune restoration in children after partial splenectomy.
Splenectomy (SE) is recognized to be a therapeutical approach in treating children with severe autoimmune diseases (chronic idiopathic thrombocytopenia; hemolytic anemia) or hypersplenism because of portal hypertension. Nevertheless, removal of a main immune organ results in elevated infection risk for these patients. Partial splenectomy (PSE) was developed as a therapeutical compromise to retain immunologically active spleen tissue. Here, we document the analysis of immune parameters obtained from children after both partial and total splenectomy, which have been followed up for a period of more than 6 years: (i) Lymphocytes from both groups of patients failed to produce IgG in response to pokeweed mitogen in vitro. This was observed in 11/20 splenectomized patients even 10 years after operation, whereas in PSE patients a restoration of this parameter after 1-2 years was seen. (ii) In patients after PSE, but not in splenectomized persons, an elevated number of HLA-class II positive cells had been detected suggesting a different situation of immune regulation following this operation. However, in parallel with an improvement of B cell in vitro activity this parameter was found to achieve normal values. Our findings indicate that partial splenectomy may be a therapeutical alternative, if the therapeutic goal can be achieved by this procedure.
Jahn
S
S
Institute for Medical Immunology, Medical Faculty (Charité), Humboldt University, Berlin, Germany.
Bauer
B
B
Schwab
J
J
Kirchmair
F
F
Neuhaus
K
K
Kiessig
S T
ST
Volk
H D
HD
Mau
H
H
von Baehr
R
R
Specht
U
U
D000293:Adolescent; D000744:Anemia, Hemolytic, Autoimmune / Q000276:immunology / Q000601:surgery; D000907:Antibodies, Bacterial / Q000096:biosynthesis; D001327:Autoimmune Diseases / Q000276:immunology* / Q000601:surgery*; D001428:Bacterial Vaccines / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D005260:Female; D006681:HLA-D Antigens / Q000378:metabolism; D006801:Humans; D006971:Hypersplenism / Q000276:immunology / Q000601:surgery; D007074:Immunoglobulin G / Q000096:biosynthesis; D066298:In Vitro Techniques; D008213:Lymphocyte Activation; D016131:Lymphocyte Subsets / Q000276:immunology; D008218:Lymphocytosis / Q000209:etiology; D008297:Male; D022242:Pneumococcal Vaccines; D013156:Splenectomy; D013296:Streptococcus pneumoniae / Q000276:immunology; D013921:Thrombocytopenia / Q000276:immunology / Q000601:surgery; D013997:Time Factors
D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D006681:HLA-D Antigens; D007074:Immunoglobulin G; D022242:Pneumococcal Vaccines